Tuesday, November 24, 2020

Maxim Group lifts Zosano Pharma Corporation [ZSAN] price estimate. Who else is bullish?

Must read

One Way Or Another, Maxar Technologies (MAXR) Will Be Benefited From NASA’s Initiatives

Maxar Technologies Inc (MAXR) is a space technology corporation which designs components for the lunar program, builds satellites for NASA and offers remote sensing...

U.S. Indices Started The Week Well, Oil Sector Also Gained

On the back of growing market operation and the results of testing another vaccine, our indexes rose Key-U.S. indices closed in the green zone on...

Teledyne Technologies (TDY) Stock Just Missed Its 52-Week High On Wednesday

The American technology corporation Teledyne Technologies Incorporated (TDY) has won a contract of $85 million to supply components for the U.S. lunar program. As a...

Tesla, Inc. (TSLA) Joins S&P 500;Morgan Stanley Raises EV giant Price Target

Wall Street analyst goes bullish on Musk’s EV maker as they see high-margin in firm’s potential software and services segment. Moreover, Tesla’s inclusion in...

Zosano Pharma Corporation [NASDAQ: ZSAN] traded at a high on 06/15/20, posting a 1.70 gain after which it closed the day’ session at $0.92. The results of the trading session contributed to over 1442554 shares changing hands. Over the past one week, the price volatility of Zosano Pharma Corporation stands at 7.79% while the volatility over the past one month is 7.54%.

The market cap for ZSAN stock reached $48.41 million, with 54.36 million shares outstanding and 48.66 million shares in the current float. Compared to the average trading volume of 1.95M shares, ZSAN reached a trading volume of 1442554 in the most recent trading day, which is why market watchdogs consider the stock to be active.


Daily trading lessons right to your inbox

Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. We’ll cover the basics of better investing and show you how to give yourself an edge in the market.

GET FREE LESSON outside the norm.

Sponsored


What do top market gurus say about Zosano Pharma Corporation [ZSAN]?

Maxim Group have made an estimate for Zosano Pharma Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 17, 2019. While these analysts kept the previous recommendation, Piper Jaffray raised their target price to Overweight. The new note on the price target was released on March 24, 2017, representing the official price target for Zosano Pharma Corporation stock. On November 11, 2015, analysts decreased their price target for ZSAN shares from 11 to 7.

The Average True Range (ATR) for Zosano Pharma Corporation is set at 0.08 The Price to Book ratio for the last quarter was 1.39.

How has ZSAN stock performed recently?

Zosano Pharma Corporation [ZSAN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.79. With this latest performance, ZSAN shares gained by 10.28% in over the last four-week period, additionally sinking by -39.78% over the last 6 months – not to mention a drop of -66.96% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZSAN stock in for the last two-week period is set at 51.08, with the RSI for the last a single of trading hit 47.13, and the three-weeks RSI is set at 52.91 for Zosano Pharma Corporation [ZSAN]. The present Moving Average for the last 50 days of trading for this stock 0.8069, while it was recorded at 0.9231 for the last single week of trading, and 1.2825 for the last 200 days.

Zosano Pharma Corporation [ZSAN]: Deeper insight into the fundamentals

Return on Total Capital for ZSAN is now -141.21, given the latest momentum, and Return on Invested Capital for the company is -168.41. Return on Equity for this stock declined to -267.52, with Return on Assets sitting at -102.35. When it comes to the capital structure of this company, Zosano Pharma Corporation [ZSAN] has a Total Debt to Total Equity ratio set at 189.02. Additionally, ZSAN Total Debt to Total Capital is recorded at 65.40, with Total Debt to Total Assets ending up at 47.13. Long-Term Debt to Equity for the company is recorded at 128.20, with the Long-Term Debt to Total Capital now at 44.36.

Reflecting on the efficiency of the workforce at the company, Zosano Pharma Corporation [ZSAN] managed to generate an average of -$671,232 per employee.Zosano Pharma Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 0.90.

Earnings analysis for Zosano Pharma Corporation [ZSAN]

With the latest financial reports released by the company, Zosano Pharma Corporation posted -0.55/share EPS, while the average EPS was predicted by analysts to be reported at -0.56/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 1.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZSAN.

Insider trade positions for Zosano Pharma Corporation [ZSAN]

There are presently around $8 million, or 23.70% of ZSAN stock, in the hands of institutional investors. The top three institutional holders of ZSAN stocks are: AISLING CAPITAL MANAGEMENT LP with ownership of 2,718,226, which is approximately 0% of the company’s market cap and around 0.20% of the total institutional ownership; TELEMETRY INVESTMENTS, L.L.C., holding 2,607,767 shares of the stock with an approximate value of $2.35 million in ZSAN stocks shares; and VANGUARD GROUP INC, currently with $1.22 million in ZSAN stock with ownership of nearly 43% of the company’s market capitalization.

17 institutional holders increased their position in Zosano Pharma Corporation [NASDAQ:ZSAN] by around 2,657,030 shares. Additionally, 10 investors decreased positions by around 300,216 shares, while 8 investors held positions by with 6,304,100 shares. The mentioned changes placed institutional holdings at 9,261,346 shares, according to the latest SEC report filing. ZSAN stock had 8 new institutional investments in for a total of 354,999 shares, while 7 institutional investors sold positions of 285,322 shares during the same period.

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

U.S. Indices Started The Week Well, Oil Sector Also Gained

On the back of growing market operation and the results of testing another vaccine, our indexes rose Key-U.S. indices closed in the green zone on...

Unity Software (U) Stock Added 7% Last Week After Positive Quarterly Results

The stock of the game engine developer Unity Software Inc. (U) rose 5.58 percent on Friday to conclude the week at $122.80. An optimistic report...

Oil And Gold Drooped On Thursday, Markets Stimulates On Budget Support Plan

On Thursday, WTI oil dropped 0.2% to $41.74, while gold dropped 0.7% to $1,861.50 an ounce. Domestic oil inventories for the week ended November...

Tesla, Inc. (TSLA) Joins S&P 500;Morgan Stanley Raises EV giant Price Target

Wall Street analyst goes bullish on Musk’s EV maker as they see high-margin in firm’s potential software and services segment. Moreover, Tesla’s inclusion in...

Teledyne Technologies (TDY) Stock Just Missed Its 52-Week High On Wednesday

The American technology corporation Teledyne Technologies Incorporated (TDY) has won a contract of $85 million to supply components for the U.S. lunar program. As a...

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the DBTNews.com pre-market morning brief 100% free

We do not sell or share your information with anyone.